Larry Bowers joined the U.S. Anti-Doping Agency in September 2000 as the Senior Managing Director of Technical and Information Resources. As USADA’s Chief Science Officer, he was responsible for leading the research efforts into detection of prohibited substances, including sample collection and analysis, and oversees USADA’s drug testing program policy. Prior to his retirement in November 2016, he led the effort to integrate the perceptual deterrence model into anti-doping. Many of the major policy advances in anti-doping arose from USADA’s involvement in anti-doping cases such as Tyler Hamilton, Michelle Collins, Marion Jones, Floyd Landis, and Lance Armstrong, for which Bowers served as an expert witness. He was present during the federal legal action at the BALCO laboratory in 2003.
Prior to his appointment with USADA, Bowers spent eight years as the Director of Athletic Drug Testing and Toxicology Laboratory at Indiana University, an IOC-accredited laboratory. He was also a professor of Pathology and Laboratory Medicine as well as in the Department of Chemistry at the Purdue University School of Science. He was deputy director of the Athletic Drug Testing Laboratory for the 1996 Olympic Games. Previously, he was a professor at the University of Minnesota for 17 years. He has published more than 100 papers on drug testing and chemistry and is frequently invited to present at conferences and scientific meetings. Bowers earned a bachelor’s degree in chemistry from Franklin & Marshall College and completed his Ph.D. in chemistry from the University of Georgia. Bowers also serves as a consultant with various organizations, including the U.S. Food and Drug Administration Medical Devices Advisory Committee and the Substance Abuse Mental Health Service Administration.